
SPONSORED CONTENT: With global regulatory scrutiny increasing, data integrity and audit-ready traceability are non-negotiable for outsourced testing, reveals Chris Williams from Alcami.
As biopharmaceutical pipelines grow increasingly complex and global regulatory scrutiny intensifies, drug developers face mounting pressure to ensure that their testing partners deliver absolute data integrity, scientific rigor, and seamless program continuity. In this exclusive interview, Chris Williams, Executive Director of Laboratory Operations, Alcami, reveals how analytical testing providers can meet these rigorous demands, spanning everything from data compliance and advanced modalities to method lifecycle management and integrated workflows.
Embedding Data Integrity and Regulatory Compliance
Q. Biopharma sponsors are increasingly scrutinizing the data integrity and quality oversight of their testing partners. What core operational disciplines does Alcami embed across its laboratory sites to ensure every test result stands up to global regulatory expectations?
A. Alcami utilizes integrated fully electronic systems with 100% review, we embed quality and compliance into our daily communications and scheduling of work. Quality is a critical part of all activities and is at the forefront of all scientists’ and leaders’ minds while being simultaneously supported by procedural requirements.
Minimizing Discrepancies Through Lifecycle Management
Q. Out-of-specification (OOS) investigations and inconclusive lab records can delay program milestones or compromise regulatory filings. How does Alcami’s approach to method development, validation, and transfer minimize analytical discrepancies and ensure scientific rigor throughout the molecule’s lifecycle?
A. Alcami’s 47 years of analytical expertise allows us to develop robust, accurate, repeatable analytical methods for complex products. The appropriate challenges during development and validation ensure the alignment of the method to perform well within the specification windows. Replicate preparations, injections, and other built-in controls can improve error detection and prevent delays for inconclusive causes.
Adapting Analytical Strategies
Q. As drug pipelines expand beyond traditional small molecules into complex biologics, peptides, oligonucleotides, and advanced therapies, testing strategies must adapt. How does Alcami tailor its analytical and specialty testing capabilities to meet the unique stability, release, and characterization needs of these modern modalities?
A. Alcami constantly monitors new pharmaceutical developments, changes in guidelines, as well as regulator findings throughout the world. This allows us to leverage our specialty testing platforms to position customers for success with regulators regardless of the modality. There are regional and modality specific requirements that must be met and knowledge of the requirements enables us to meet all these requirements.
Guaranteeing Audit-Ready Traceability
Q. When regulatory agencies inspect a drug master file or market application, the complete lineage of laboratory records becomes a central focal point. How does Alcami partner with sponsors during regulatory reviews to ensure documentation completeness and audit-ready traceability?
A. ALCOA+++ principles are a subject of frequent trainings at Alcami. In addition to this, the ALCOA principles have to be extrapolated beyond and immediate scientist onto electronic systems and various software. Robust change control and computer system validation along with and ever present commitment to ALCOA+++ allows Alcami to treat compliance as a foundational element of our daily activities.
Safeguarding Program Continuity
Q. Transferring analytical methods between multiple disjointed vendors often introduces risk and knowledge loss. How does integrating laboratory services with broader development and manufacturing workflows protect program continuity?
A. Alcami employes harmonized quality systems and instrumentation across all of its laboratory locations. Along with strategic redundancy, this allows for Alcami to ensure continuity through multiple levels of failure. This process goes from analytical methodologies to redundancy of our redundant back-up systems for critical areas. We are privileged enough to be trusted with samples and materials that may be the only aliquots that exist in the world, and we develop our continuity plans with the patients that need these materials in mind.
Prioritizing Scientific Retention and Experience
Q. When drug developers evaluate or reassess their outsourced laboratory network, what critical quality indicators and operational benchmarks should they prioritize beyond basic capacity and timeline metrics?
A. Scientific retention, Alcami prides itself on being a solution provider not service provider. We have experience with tens of thousands of products and customers as well as almost all regulatory regions in the world. Retention of the team that has worked through complex methods allows us to forever leverage those learnings for future products and patients.
About the Interviewee
Chris Williams is the Executive Director of Laboratory Operations at Alcami, bringing more than a decade of experience in analytical development, quality control, and laboratory operations. He earned a Bachelor of Science in Chemistry in 2010 and a Master of Science in Chemistry in 2011 from East Carolina University. Chris joined AAI, now Alcami, in 2011 as a Development/QC Scientist. In 2013, he began supervising a laboratory team focused on high-throughput manufacturing release. In 2014, he moved into the management of development services and has since progressed to oversee elemental impurities, biologics, extractables and leachables, nitrosamines, specialty testing, raw material release, microbiology, and all Wilmington laboratory operations.
Image Credit: © Dilok – stock.adobe.com










